Form 4: Teva Pharma EVP Sells Shares After RSU Vesting

Richard Daniell, Teva Pharmaceutical Industries' EVP of Europe Commercial, sold ordinary shares totaling 91,345 units following the vesting of restricted share units, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Richard Daniell, EVP, Europe Commercial, of Teva Pharmaceutical Industries Ltd. (TEVA), reported multiple transactions on March 4, 2026.
• Transactions were executed under a Rule 10b5-1 trading plan adopted on November 10, 2025.
• Daniell acquired 33,512 ordinary shares through the vesting of restricted share units (RSUs) granted on March 4, 2022.
• Concurrently, he sold 33,512 ordinary shares at a weighted average price of $32.4645, covering vested shares and tax withholding obligations.
• He also acquired 20,461 ordinary shares from the vesting of RSUs granted on March 4, 2024.
• Following this, he sold 20,461 ordinary shares at a weighted average price of $32.4645, also covering vested shares and tax withholding.
• An additional 37,372 ordinary shares were sold at a weighted average price of $32.9474.
• A new grant of 33,424 restricted share units was made on March 4, 2026, with vesting scheduled annually from March 4, 2027, to March 4, 2030.
• Following these transactions, Daniell's direct beneficial ownership of ordinary shares is 85,755, and derivative securities (RSUs) is 33,424.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it primarily reflects routine executive compensation and personal financial management through a pre-arranged trading plan, rather than a signal of company performance or a change in executive confidence.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to insider stock sales.
• The sale of shares to cover tax withholding obligations is a standard practice for RSU vesting.
• A new grant of 33,424 restricted share units on March 4, 2026, indicates continued long-term incentive alignment for the executive.

Negatives

• The executive sold a significant number of shares (91,345 total) following vesting, which reduces their direct equity stake in the company.

Future Outlook

The filing indicates future vesting of restricted share units for Richard Daniell, with 8,356 units vesting annually from March 4, 2027, to March 4, 2030, from a new grant on March 4, 2026. This suggests continued long-term incentive alignment for the executive.

Industry Context

StockSavvy.ai notes that executive stock sales following RSU vesting are a common occurrence in the pharmaceutical industry, often driven by personal financial planning and tax obligations. The use of a Rule 10b5-1 plan is a standard practice for executives to manage their equity holdings transparently and avoid accusations of insider trading.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of executive compensation involving Restricted Share Units (RSUs) and subsequent sales to cover tax obligations upon vesting is a widely adopted practice across global industries, including major pharmaceutical companies like Pfizer, Novartis, and Johnson & Johnson.
• The adoption of a Rule 10b5-1 trading plan by Richard Daniell aligns with best practices for corporate governance and transparency in executive stock transactions, similar to those implemented by executives at comparable firms to mitigate insider trading concerns.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by an executive could be perceived as a slight reduction in insider alignment, though mitigated by the 10b5-1 plan and new RSU grant.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• Future vesting of 8,356 Restricted Share Units on March 4, 2027.
• Future vesting of 8,356 Restricted Share Units on March 4, 2028.
• Future vesting of 8,356 Restricted Share Units on March 4, 2029.
• Future vesting of 8,356 Restricted Share Units on March 4, 2030.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation and planned stock sales under a 10b5-1 plan. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The executive's continued receipt of RSU grants suggests ongoing alignment with long-term company performance, while the sales are typical for tax and personal liquidity purposes. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Trading, Richard Daniell, Restricted Share Units, RSU Vesting, Stock Sale, Rule 10b5-1, Executive Compensation, Beneficial Ownership